Advertisement

Neuro-Urology pp 249-281 | Cite as

Infections in Neuro-urology

  • Muhammad RasheedEmail author
  • Arndt van Ophoven
Chapter
First Online:

Abstract

There is a high incidence of recurrent cystitis and complicated urinary tract infection in patients with neurogenic bladder. Adequate bladder management can reduce the episodes of recurrent infection and urinary incontinence in neurogenic bladder dysfunction. Inappropriate treatment of urinary tract infection can damage the renal functions due to reflex pyelonephritis and vesicoureteral reflux. The better understanding of functional urology improves the quality of life in patients with neurogenic bladder.

This chapter emphasizes the relevance and impact of infections of the urinary tract in neuro-urology. It provides not only the information of global epidemiological causes, diagnosis, and treatment of urinary tract infection but also helpful tools to decrease the incidence of recurrent bladder infections in neuro-urology and to reduce the antimicrobial resistance worldwide.

Advanced microbiological technologies for the detection of responsible infection agents are helpful to minimize urosepsis. The application of sequential organ failure assessment score in intensive care unit reduces the high economic burden on the society while achieving sufficient reduction in morbidity and mortality of patients.

This chapter should be of interest to many different professionals, medical students, medical, surgical residents, as well as consultants in urology and infectious diseases.

Keywords

Recurrent infection Urinary incontinence Neurogenic bladder dysfunction Antimicrobial resistance Nonsurgical bladder management in neuro-urology 

Abbreviations

ACSS

Acute cystitis symptom score

ACTH

Adrenocorticotrophic hormone

AUC

Acute urinary cystitis

BPH

Benign prostatic hyperplasia

CA

Catheter associated

CA-AB

Catheter-associated bacteriuria

CA-AB

Catheter-associated asymptomatic bacteriuria

CA-UTI

Catheter-associated urinary tract infection

CAUTI

Community-associated UTI

CFU

Colony forming unit

CIC

Clean intermittent catheterization

DSD

Detrusor sphincter dyssynergia

DSD

Detrusor sphincter dyssynergia

ESBL

Extended-spectrum beta-lactamase

GAG

Glycosaminoglycan

HAUTI

Healthcare-associated urinary tract infection

IC

Indwelling catheter

IDSA

Infectious Disease Society of America

IL

Interleukin

MDR

Multidrug-resistant

MRSA

Methicillin-resistant Staphylococcus aureus

MS

Multiple sclerosis

NAUTI

Nosocomial urinary tract infections

NB

Neurogenic bladder

NDO

Neurogenic detrusor overactivity

NF-kB

Nuclear factor kappa-light-chain-enhancer of activated B cells

qSOFA

Quick sequential (sepsis-related) organ failure assessment

SCI

Spinal cord injury

S-IgA

Secretory immunoglobulin-A

SOFA

Sequential (sepsis-related) organ failure assessment

SPC

Supra pubic catheterization

TLR

Toll-like receptors

TMP-SMX

Trimethoprim-sulfamethoxazole

TNF

Tumor necrosis factor

UDS

Urodynamics

UTI

Urinary tract infection

VUDS

Video urodynamics

VUR

Vesicoureteral reflux

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73–9.  https://doi.org/10.1097/QCO.0000000000000228.CrossRefPubMedGoogle Scholar
  2. 2.
    Gardner A, Mitchell B, Beckingham W, Fasugba O. A point prevalence cross-sectional study of healthcare-associated urinary tract infections in six Australian hospitals. BMJ Open. 2014;4(7):e005099.  https://doi.org/10.1136/bmjopen-2014-005099.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Graves N, Tong E, Morton AP, Halton K, Curtis M, Lairson D, et al. Factors associated with health care-acquired urinary tract infection. Am J Infect Control. 2007;35(6):387–92.  https://doi.org/10.1016/j.ajic.2006.09.006.CrossRefPubMedGoogle Scholar
  4. 4.
    World health organization: Health care-associated infections fact sheet, http://www.who.int/gpsc/country_work/gpsc_ccisc_fact_sheet_en.pdf. Accessed 7 Oct 2015.
  5. 5.
    Togan T, Azap OK, Durukan E, Arslan H. The prevalence, etiologic agents and risk factors for urinary tract infection among spinal cord injury patients. Jundishapur J Microbiol. 2014;7(1):e8905.  https://doi.org/10.5812/jjm.8905.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Martins CF, Bronzatto E, Neto JM, Magalhaes GS, D'Anconna CA, Cliquet A Jr. Urinary tract infection analysis in a spinal cord injured population undergoing rehabilitation—how to treat? Spinal Cord. 2013;51(3):193–5.  https://doi.org/10.1038/sc.2012.104.CrossRefPubMedGoogle Scholar
  7. 7.
    Yoon SB, Lee BS, Lee KD, Hwang SI, Lee HJ, Han ZA. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord. 2014;52(4):298–301.  https://doi.org/10.1038/sc.2014.10.CrossRefPubMedGoogle Scholar
  8. 8.
    Esclarin De Ruz A, Garcia Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164(4):1285–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Vigil HR, Hickling DR. Urinary tract infection in the neurogenic bladder. Transl Androl Urol. 2016;5(1):72–87.  https://doi.org/10.3978/j.issn.2223-4683.2016.01.06.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(6):663–76.  https://doi.org/10.1586/erv.12.36.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–84.  https://doi.org/10.1038/nrmicro3432.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Grabe M, Bartoletti R, Bjerklund Johansen TE, Cai T, Çek M, Köves B, Naber KG, Pickard RS, Tenke P, Wagenlehner F, Wullt B. Guidelines on Urological Infections. European Association of Urology. 2015.Google Scholar
  13. 13.
    Neal DE Jr. Host defense mechanisms in urinary tract infections. Urol Clin North Am. 1999;26(4):677–86. viiCrossRefPubMedGoogle Scholar
  14. 14.
    Merritt JL. Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury. Arch Phys Med Rehabil. 1981;62(11):558–61.PubMedGoogle Scholar
  15. 15.
    Vasudeva P, Madersbacher H. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. NeurourolUrodyn. 2014;33(1):95–100.  https://doi.org/10.1002/nau.22378.CrossRefGoogle Scholar
  16. 16.
    Waites KB, Canupp KC, DeVivo MJ. Microbiology of the urethra and perineum and its relationship to bacteriuria in community-residing men with spinal cord injury. J Spinal Cord Med. 2004;27(5):448–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Parsons CL, Greenspan C, Moore SW, Mulholland SG. Role of surface mucin in primary antibacterial defense of bladder. Urology. 1977;9(1):48–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Parsons CL, Shrom SH, Hanno PM, Mulholland SG. Bladder surface mucin. Examination of possible mechanisms for its antibacterial effect. Invest Urol. 1978;16(3):196–200.PubMedGoogle Scholar
  19. 19.
    Wold AE, Mestecky J, Tomana M, Kobata A, Ohbayashi H, Endo T, et al. Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect Immun. 1990;58(9):3073–7.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Vaidyanathan S, McDicken IW, Soni BM, Singh G, Sett P, Husin NM. Secretory immunoglobulin A in the vesical urothelium of patients with neuropathic bladder—an immunohistochemical study. Spinal Cord. 2000;38(6):378–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Chaudhry R, Madden-Fuentes RJ, Ortiz TK, Balsara Z, Tang Y, Nseyo U, et al. Inflammatory response to Escherichia coli urinary tract infection in the neurogenic bladder of the spinal cord injured host. J Urol. 2014;191(5):1454–61.  https://doi.org/10.1016/j.juro.2013.12.013.CrossRefPubMedGoogle Scholar
  22. 22.
    Iversen PO, Hjeltnes N, Holm B, Flatebo T, Strom-Gundersen I, Ronning W, et al. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. Blood. 2000;96(6):2081–3.PubMedGoogle Scholar
  23. 23.
    Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol. 2012;187(2):391–7.  https://doi.org/10.1016/j.juro.2011.10.020.CrossRefPubMedGoogle Scholar
  25. 25.
    Jayawardena V, Midha M. Significance of bacteriuria in neurogenic bladder. J Spinal Cord Med. 2004;27(2):102–5.CrossRefPubMedGoogle Scholar
  26. 26.
    El Masri y WS, Patil S, Prasanna KV, Chowdhury JR. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord. 2014;52(1):49–53.  https://doi.org/10.1038/sc.2013.119.CrossRefPubMedGoogle Scholar
  27. 27.
    Salameh A, Al Mohajer M, Daroucihe RO. Prevention of urinary tract infections in patients with spinal cord injury. CMAJ. 2015;187(11):807–11.  https://doi.org/10.1503/cmaj.141044.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Goetz LL, Cardenas DD, Kennelly M, Bonne Lee BS, Linsenmeyer T, Moser C, et al. International spinal cord injury urinary tract infection basic data set. Spinal Cord. 2013;51(9):700–4.  https://doi.org/10.1038/sc.2013.72.CrossRefPubMedGoogle Scholar
  29. 29.
    Ronco E, Denys P, Bernede-Bauduin C, Laffont I, Martel P, Salomon J, et al. Diagnostic criteria of urinary tract infection in male patients with spinal cord injury. Neurorehabil Neural Repair. 2011;25(4):351–8.  https://doi.org/10.1177/1545968310383432.CrossRefPubMedGoogle Scholar
  30. 30.
    Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med. 2002;113(Suppl 1A):67s–79s.CrossRefPubMedGoogle Scholar
  31. 31.
    Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–9.  https://doi.org/10.1016/j.ijid.2011.07.007.CrossRefPubMedGoogle Scholar
  32. 32.
    Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364–86.CrossRefPubMedGoogle Scholar
  33. 33.
    Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians. 1956;69:56–64.PubMedGoogle Scholar
  34. 34.
    Warren JW, Platt R, Thomas RJ, Rosner B, Kass EH. Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med. 1978;299(11):570–3.  https://doi.org/10.1056/nejm197809142991103.CrossRefPubMedGoogle Scholar
  35. 35.
    Platt R, Polk BF, Murdock B, Rosner B. Reduction of mortality associated with nosocomial urinary tract infection. Lancet. 1983;1(8330):893–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Garibaldi RA, Burke JP, Dickman ML, Smith CB. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med. 1974;291(5):215–9.  https://doi.org/10.1056/nejm197408012910501.CrossRefPubMedGoogle Scholar
  37. 37.
    Hartstein AI, Garber SB, Ward TT, Jones SR, Morthland VH. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control. 1981;2(5):380–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Tenney JH, Warren JW. Bacteriuria in women with long-term catheters: paired comparison of indwelling and replacement catheters. J Infect Dis. 1988;157(1):199–202.CrossRefPubMedGoogle Scholar
  39. 39.
    Grahn D, Norman DC, White ML, Cantrell M, Yoshikawa TT. Validity of urinary catheter specimen for diagnosis of urinary tract infection in the elderly. Arch Intern Med. 1985;145(10):1858–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Cruz F, Nitti V. Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). NeurourolUrodyn. 2014;33(Suppl 3):S26–31.  https://doi.org/10.1002/nau.22630.CrossRefGoogle Scholar
  41. 41.
    Leitner L, Sammer U, Walter M, Knupfer SC, Schneider MP, Seifert B, et al. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep. 2016;6:33197.  https://doi.org/10.1038/srep33197.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010;67(1):74–84.  https://doi.org/10.1002/ana.21814.CrossRefPubMedGoogle Scholar
  43. 43.
    Darouiche RO, Green BG, Donovan WH, Chen D, Schwartz M, Merritt J, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology. 2011;78(2):341–6.  https://doi.org/10.1016/j.urology.2011.03.062.CrossRefPubMedGoogle Scholar
  44. 44.
    Montgomerie JZ, Morrow JW. Long-term Pseudomonas colonization in spinal cord injury patients. Am J Epidemiol. 1980;112(4):508–17.CrossRefPubMedGoogle Scholar
  45. 45.
    Montgomerie JZ, Gilmore DS, Graham IE, Schick DG, Ashley MA, Morrow JW, et al. Klebsiella pneumoniae colonization in patients with spinal cord injury. Diagn Microbiol Infect Dis. 1987;7(4):229–35.CrossRefPubMedGoogle Scholar
  46. 46.
    Shen L, Zheng X, Zhang C, Zeng B, Hou C. Influence of different urination methods on the urinary systems of patients with spinal cord injury. J Int Med Res. 2012;40(5):1949–57.  https://doi.org/10.1177/030006051204000536.CrossRefPubMedGoogle Scholar
  47. 47.
    Prieto J, Murphy CL, Moore KN, Fader M. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev. 2014;(9):Cd006008.  https://doi.org/10.1002/14651858.CD006008.pub3.
  48. 48.
    Siddiq DM, Darouiche RO. New strategies to prevent catheter-associated urinary tract infections. Nat Rev Urol. 2012;9(6):305–14.  https://doi.org/10.1038/nrurol.2012.68.CrossRefPubMedGoogle Scholar
  49. 49.
  50. 50.
    Opperman EA. Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury. Spinal Cord. 2010;48(6):451–6.  https://doi.org/10.1038/sc.2009.159.CrossRefPubMedGoogle Scholar
  51. 51.
    Hess MJ, Hess PE, Sullivan MR, Nee M, Yalla SV. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord. 2008;46(9):622–6.  https://doi.org/10.1038/sc.2008.25.CrossRefPubMedGoogle Scholar
  52. 52.
    Morton SC, Shekelle PG, Adams JL, Bennett C, Dobkin BH, Montgomerie J, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil. 2002;83(1):129–38.CrossRefPubMedGoogle Scholar
  53. 53.
    Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect. 2001;7(10):523–31.CrossRefPubMedGoogle Scholar
  54. 54.
    Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2003;45(4):295–301.CrossRefPubMedGoogle Scholar
  55. 55.
    DasGupta R, Sullivan R, French G, O'Brien T. Evidence-based prescription of antibiotics in urology: a 5-year review of microbiology. BJU Int. 2009;104(6):760–4.  https://doi.org/10.1111/j.1464-410X.2009.08779.x.CrossRefPubMedGoogle Scholar
  56. 56.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.CrossRefGoogle Scholar
  57. 57.
    Tandogdu Z, Bartoletti R, Cai T, Cek M, Grabe M, Kulchavenya E, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol. 2016;34(8):1193–200.  https://doi.org/10.1007/s00345-015-1722-1.CrossRefPubMedGoogle Scholar
  58. 58.
    Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32(3):791–801.  https://doi.org/10.1007/s00345-013-1154-8.CrossRefPubMedGoogle Scholar
  59. 59.
    Melican K, Boekel J, Mansson LE, Sandoval RM, Tanner GA, Kallskog O, et al. Bacterial infection-mediated mucosal signalling induces local renal ischaemia as a defence against sepsis. Cell Microbiol. 2008;10(10):1987–98.  https://doi.org/10.1111/j.1462-5822.2008.01182.x.CrossRefPubMedGoogle Scholar
  60. 60.
    Wagenlehner FM, Pilatz A, Weidner W, Naber KG. Urosepsis: overview of the diagnostic and treatment challenges. Microbiol Spectr. 2015;3(5).  https://doi.org/10.1128/microbiolspec.UTI-0003-2012.
  61. 61.
    Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, et al. The global prevalence of infections in urology study: a long-term, worldwide surveillance study on urological infections. Pathogens. 2016;5(1):E10.  https://doi.org/10.3390/pathogens5010010.CrossRefPubMedGoogle Scholar
  62. 62.
    Dinh A, Davido B, Calin R, Paquereau J, Duran C, Bouchand F, et al. Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder. Spinal cord Ser Cases. 2017;3:17019.  https://doi.org/10.1038/scsandc2017.19.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.  https://doi.org/10.1001/jama.2016.0287.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176(9):1266–76.  https://doi.org/10.1001/jamainternmed.2016.2514.CrossRefPubMedGoogle Scholar
  65. 65.
    Zaccone V, Tosoni A, Passaro G, Vallone C, Impagnatiello M, Li Puma DD, et al. Sepsis in internal medicine wards: current knowledge, uncertainties and new approaches for management optimization. Ann Med. 2017:1–26.  https://doi.org/10.1080/07853890.2017.1332776.
  66. 66.
    Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.  https://doi.org/10.1007/s00134-017-4683-6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neuro-UrologyMarien Hospital Herne, University Clinic Bochum, The Ruhr University BochumHerneGermany

Personalised recommendations

Cite chapter

Buy options